Nasonova Alla
1 Papers
Nasonova Alla is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Gemcitabine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes,David W. Cescon,Hope S. Rugo,Zbigniew Nowecki,Seock-Ah Im,Mastura Md Yusof,Carlos Gallardo,Oleg Lipatov,Carlos H. Barrios,Esther Holgado,Hiroji Iwata,Norikazu Masuda,Marco Torregroza Otero,Erhan Gokmen,Sherene Loi,Zifang Guo,Jing Zhao,Gursel Aktan,Vassiliki Karantza,Peter Schmid,Fein Luis,Gomez Abuin Gonzalo,Kaen Diego,Kowalwszyn Ruben,Molina Matias,Varela Mirta,Baron-Hay Sally,Begbie Stephen,Clingan Philip,Loi Sherene,Sabanathan Dhanusha,Gombos Andrea,Taylor Donatienne,Barrios Carlos,Brust Leandro,Costa Fabiano,de Freitas Junior Ruffo,Hegg Roberto,Lacerda Domicio Carvalho,Lissa Fernando Cezar Toniazzi,Rocha Roberto Odebrecht,Scalabrini Neto Antonio Orlando,Silva Felipe,Cescon David,Charpentier Danielle,Ferrario Cristiano,Song Xinni,Yu Joanne,Acevedo Alejandro,Gallardo Carlos,Salas Claudio,Sanchez Cesar,Yanez Eduardo,Gomez Diaz Alvaro,Sanchez Jesus,Holeckova Petra,Kral Zdenek,Melichar Bohuslav,Petrakova Katarina,Prausova Jana,Glavicic Vesna,Jakobsen Erik,Jensen Jeanette,Linnet Soren,Lorincz Tamas,Bonnefoi Herve,Desmoulins Isabelle,Goncalves Anthony,Hardy-Bessard Anne-Claire,Teixeira Luis,Blohmer Jens-Uwe,Fasching Peter,Forstmeyer Dirk,Harbeck Nadia,Huober Jens,Kaczerowsky Flores de Sousa Anna,Kurbacher Christian,Loibl Sibylle,Lueftner Diana,Park-Simon Tjoung-Won,Schumann Raquel Von,Wimberger Pauline,Chow Louis,Kwong Ava,Ngan Kai Cheong Roger,Arkosy Peter,Csoszi Tibor,Kahan Zsuzsanna,Landherr Laszlo,Mahr Karoly,Rubovszky Gabor,Crown John,Kelly Catherine,O'Reilly Seamus,Cinieri Saverio,DAlessio Antonietta,Ricevuto Enrico,Aruga Tomoyuki,Fujii Takaaki,Inoue Kenichi,Ishikawa Takashi,Ito Yoshinori,Iwasa Tsutomu,Iwata Hiroji,Kosaka Yoshimasa,Matsumoto Koji,Miyoshi Yasuo,Mukai Hirofumi,Nakamura Seigo,Niikura Naoki,Ohtani Shoichiro,Osaki Akihiko,Sagara Yasuaki,Suzuki Eiji,Takahashi Masato,Tanabe Yuko,Tamura Kenji,Tsugawa Koichiro,Watanabe Junichiro,Yamamoto Naohito,Yamamoto Yutaka,Yamauchi Teruo,Bustam Anita,Yusof Mastura,Gomez Villanueva Angel,Juarez Ramiro Alejandro,Martinez Rodriguez Jorge,Morales-Vasquez Flavia,Reyes Contreras Jessica,Beelen Karin,Tjan-Heijnen Vivianne,Porter David,Chmielowska Ewa,Nowakowska-Zajdel Ewa,Nowecki Zbigniew,Radecka Barbara,Streb Joanna,Szczylik Cezary,Tarnawski Rafal,Zurawski Bogdan,Arkhipov Alexander,Fadeeva Natalia,Lipatov Oleg,Meshcheryakov Andrey,Moiseyenko Vladimir,Mukhametshina Guzel,Ahn Jin Hee,Im Seock-Ah,Lee Keun Seok,Park Kwong Hwa,Park Yeon Hee,Bermejo de las Heras Begona,Cortes Javier,Cruz Jurado Josefina,de la Cruz Merino Luis,Garcia Saenz Jose,Gion Maria,Holgado Esther,Zamora Adelantado Esther,Liu Chien-Ting,Liu Mei-Ching,Huang Chiun-Sheng,Tsao Chao-Jung,Tseng Ling-Ming,Arslan Cagatay,Basaran Gul,Cicin Irfan,Gokmen Erhan,Gunduz Seyda,Molinas Mandel Nil,Ozguroglu Mustafa,Ozyilkan Ozgur,Yavuz Sinan,Chan Steve,Graham Janine,MacPherson Iain,Schmid Peter,Turner Nicholas,Tuthill Mark,Twelves Christopher,Wheatley Duncan,Adamchuk Hryhoriy,Berzoy Oleksandr,Bondarenko Igor,Kolesnik Oleksii,Kolesnik Olena,Komisarenko Hanna,Kryzhanivska Anna,Leshchenko Iurii,Nasonova Alla,Otchenash Natalya,Ponomarova Olga,Rusyn Andrii,Shevnya Sergii,Shparyk Yaroslav,Trukhin Dmytro,Ursol Grygorii,Vynnychenko Ihor,Blau Sibel,Chaudhry Madhu,Chung Michael,Cobb Patrick,Cole Scott,Diamond Jennifer,Gogineni Keerthi,Hargis Jeffrey,Hoskins Kent,Irvin William,Loutfi Randa,Lu Janice,Mena Raul,Moore Susan,Nanda Rita,Oliff Ira,Omene Coral,Panella Timothy,Panwalkar Amit,Patson Brian,Rugo Hope,Rybalova Irina,Schleider Michael,Siegel Robert,Simon Michael,Stampleman Laura,Sumrall Bradley,Tsai Michaela,Valdes-Albini Frances +226 more
TL;DR: Whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in patients with metastatic triple-negative breast cancer was examined to assess overall survival and progression-free survival.
1.4K